Mark M. Kowalski
Chief Tech/Sci/R&D Officer chez EUPRAXIA PHARMACEUTICALS INC.
Fortune : 25 920 $ au 31/03/2024
Profil
Mark M.
Kowalski is currently the Chief Medical Officer at Eupraxia Pharmaceuticals, Inc. Prior to this, he held the position of Chief Research & Early Development Officer at Sierra Oncology, Inc. from 2017 to 2022.
He also served as the Chief Medical Officer & Senior Vice President at Arbutus Biopharma Corp.
from 2013 to 2016.
Before that, he was the Chief Medical Officer & VP-Regulatory Affairs at Viventia Biotech, Inc. and YM BioSciences, Inc. He also worked as the Senior Director-Medical Affairs at AAIPharma, Inc. Dr. Kowalski received his undergraduate degree from Rutgers State University of New Jersey and his doctorate from the University of Kansas Medical School.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 18/08/2023 | 8 000 ( 0,03% ) | 25 920 $ | 31/03/2024 |
Postes actifs de Mark M. Kowalski
| Sociétés | Poste | Début |
|---|---|---|
| EUPRAXIA PHARMACEUTICALS INC. | Chief Tech/Sci/R&D Officer | 18/05/2023 |
Anciens postes connus de Mark M. Kowalski
| Sociétés | Poste | Fin |
|---|---|---|
| SIERRA ONCOLOGY, INC. | Chief Tech/Sci/R&D Officer | 10/03/2022 |
| ARBUTUS BIOPHARMA CORPORATION | Chief Tech/Sci/R&D Officer | 30/09/2016 |
Viventia Bio, Inc.
 Viventia Bio, Inc. BiotechnologyHealth Technology Viventia Bio, Inc. operates as a biologics oncology company, which focuses on designing, engineering, and developing targeted protein therapeutics. The company was founded by Leslie Lewis Dan in October 2012 and is headquartered in Winnipeg, Canada. | Chief Tech/Sci/R&D Officer | - |
AAIPharma, Inc.
 AAIPharma, Inc. Miscellaneous Commercial ServicesCommercial Services AAIPharma, Inc. provides product development services to the pharmaceutical, biotechnology and medical device industries. Its services include drug delivery technologies, contract manufacturing, clinical packaging and distribution and bioanalytical services. The company was founded in 1979 and is headquartered in Wilmington, NC. | Chief Tech/Sci/R&D Officer | - |
Viventia Biotech, Inc.
 Viventia Biotech, Inc. BiotechnologyHealth Technology Viventia Biotech, Inc. discovers, develops, manufactures, and commercializes monoclonal antibody products. Its products are used to treat head, neck, and bladder cancers. The company was founded by Albert D. Friesen in 1995 and is headquartered in Toronto, Canada | Chief Tech/Sci/R&D Officer | - |
Formation de Mark M. Kowalski
| Rutgers State University of New Jersey | Undergraduate Degree |
| University of Kansas Medical School | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| ARBUTUS BIOPHARMA CORPORATION | Health Technology |
| EUPRAXIA PHARMACEUTICALS INC. | Health Technology |
| Entreprise privées | 5 |
|---|---|
AAIPharma, Inc.
AAIPharma, Inc. Miscellaneous Commercial ServicesCommercial Services AAIPharma, Inc. provides product development services to the pharmaceutical, biotechnology and medical device industries. Its services include drug delivery technologies, contract manufacturing, clinical packaging and distribution and bioanalytical services. The company was founded in 1979 and is headquartered in Wilmington, NC. | Commercial Services |
YM BioSciences, Inc.
 YM BioSciences, Inc. Pharmaceuticals: MajorHealth Technology YM BioSciences, Inc. operates as a drug development company, which manufactures advancing hematology and cancer-related products. It is currently advancing in late-stage products, which include CYT387, an oral small molecule inhibitor of the kinase enzymes JAK1 and JAK2; and Nimotuzumab, an EGFR targeting humanized monoclonal antibody. The company was founded in 1994 and is headquartered in Mississauga, Canada. | Health Technology |
Viventia Biotech, Inc.
Viventia Biotech, Inc. BiotechnologyHealth Technology Viventia Biotech, Inc. discovers, develops, manufactures, and commercializes monoclonal antibody products. Its products are used to treat head, neck, and bladder cancers. The company was founded by Albert D. Friesen in 1995 and is headquartered in Toronto, Canada | Health Technology |
Sierra Oncology, Inc.
 Sierra Oncology, Inc. BiotechnologyHealth Technology Sierra Oncology, Inc. was a clinical stage drug development company of therapeutics for the treatment of cancer. The firm focused on advanced targeted therapeutics for the treatment of patients with significant unmet medical needs in hematology and oncology. Its product Momelotinib, a selective and orally-bioavailable JAK1, JAK2 & ACVR1 inhibitor with a differentiated therapeutic profile in myelofibrosis encompassing robust constitutional symptom improvements. The company was founded in May 2003 and is headquartered in San Mateo, CA. | Health Technology |
Viventia Bio, Inc.
Viventia Bio, Inc. BiotechnologyHealth Technology Viventia Bio, Inc. operates as a biologics oncology company, which focuses on designing, engineering, and developing targeted protein therapeutics. The company was founded by Leslie Lewis Dan in October 2012 and is headquartered in Winnipeg, Canada. | Health Technology |
